Transcenta

Transcenta, with the slogan INNOVATE TO EXCEL, is a clinical-stage biopharmaceutical company committed to the full integration of antibody-based biotherapeutics discovery, research, development, and manufacturing.

Founded in 2019, Transcenta has made significant strides in the industry, solidifying its presence across a global landscape. With its headquarters in the United States, the company extends its reach with research and development centers across major Chinese cities like Suzhou, Beijing, Shanghai, and Guangzhou, as well as in Princeton, US. It also boasts external partnering centers in Boston and Los Angeles, US.

Listed on the Main Board of the Stock Exchange of Hong Kong Limited, Transcenta continues to advance its development pipeline, which includes nine therapeutic antibody molecules targeting oncology and non-oncology conditions such as bone and kidney disorders.

In a recent financial maneuver, the company secured a HKD59.34M post-IPO equity investment as of 01 September 2025, positioning it strongly for continued innovation and market impact.